John B. Copley
Cleveland Clinic
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by John B. Copley.
Transplantation | 2005
Daniel A. Shoskes; Chantale Lapierre; Marcia Cruz-Corerra; Nicolas Muruve; Reinaldo Rosario; Beth Fromkin; Mauro Braun; John B. Copley
Background. The bioflavonoids quercetin and curcumin are renoprotective natural antioxidants. We wished to examine their effects on early graft function (EF). Methods. Between September 2002 and August 2004, 43 dialysis dependent cadaveric kidney recipients were enrolled into a study using Oxy-Q which contains 480 mg of curcumin and 20 mg of quercetin, started after surgery and taken for 1 month. They were randomized into three groups: control (placebo), low dose (one capsule, one placebo) and high dose (two capsules). Delayed graft function (DGF) was defined as first week dialysis need and slow function (SGF) as Cr >2.5 mg/dl by day 10. Category variables were compared by chi squared and continuous variables by Kruskal-Wallis. Results. There were four withdrawals: one by patient choice and three for urine leak. The control group had 2/14 patients with DGF vs. none in either treatment group. Incidence of EF was control 43%, low dose 71% and high dose 93% (P=0.013). Serum creatinine was significantly lower at 2 days (control 7.6±2.1, low 5.4±0.6, high 3.96±.35 P=0.0001) and 30 days (control 1.82±.16, low 1.65±.09, high 1.33 ±.1, P=0.03). Acute rejection incidence within 6 months was control 14.3%, low dose 14.3% and high dose 0%. Tremor was detected in 13% of high dose patients vs. 46% of others. Urinary HO-1 was higher in bioflavonoid groups. Conclusion. Bioflavonoid therapy improved early graft function. Acute rejection and neurotoxicity were lowest in the high dose group. These bioflavonoids improve early outcomes in cadaveric renal transplantation, possibly through HO-1 induction.
Obesity Surgery | 2005
Flavia Soto; Guillermo Higa-Sansone; John B. Copley; Mariana Berho; Colleen Kennedy; Emanuelle LoMenzo; David Podkameni; Samuel Szomstein; Raul J. Rosenthal
There is experimental evidence but very few human studies that suggest a role for obesity in the formation and progression of some glomerular lesions. We report the case of a morbidly obese male with hematuria and proteinuria that was subsequently diagnosed with renal failure which required dialysis. Histological findings of the renal biopsy performed during a laparoscopic gastric bypass are presented. His renal failure resolved with the weight loss.
Clinical Transplantation | 2011
John B. Copley; Rudolf P. Wüthrich
Copley JB, Wüthrich RP. Therapeutic management of post‐kidney transplant hyperparathyroidism. Clin Transplant 2011: 25: 24–39.
Transplantation | 1999
Nasimul Ahsan; Donald E. Hricik; Arthur J. Matas; Stephen Rose; Stephen J. Tomlanovich; Alan H. Wilkinson; Marian Ewell; Matthew McIntosh; Donald Stablein; Ernest Hodge; Daniel Hayes; Paul F. Gores; David Cohen; Thomas A. Gonwa; Karl Brinler; Robert C. Harland; John F. Neylan; Mark D. Pescovitz; James J. Wynn; Harold C-Yang; William M. Bennett; John B. Copley; John Dunn; S. Tomlanovich; Lawrence Chan; J. Andrew Bertolatus; Mathew Weir; Robert Mendez; John D. Pirsch; J. Harold Helderman
American Journal of Kidney Diseases | 2005
Amaryllis Pascual; Howard S. Bush; John B. Copley
Dm Disease-a-month | 2005
John B. Copley; Reinaldo Rosario
Transplantation Proceedings | 2003
Daniel A. Shoskes; M. Thomas; R. Pobgee; Beth Fromkin; John B. Copley
Journal of Clinical Hypertension | 2006
John B. Copley
American Journal of Kidney Diseases | 2007
Rute Paixao; Mauro Braun; John B. Copley; Beth Fromkin; Arun Amatya
Transplantation | 2006
Daniel A. Shoskes; Chantale Lapierre; Marcia Cruz-Correa; Nicolas Muruve; Reinaldo Rosario; Beth Fromkin; Mauro Braun; John B. Copley